Home›Stock Screener›Welcure Drugs & Pharmaceuticals›Financial Statements

Welcure Drugs & Pharmaceuticals Complete Financial Statements

12 Years of Data
2026 - 2015

In FY2026, Welcure Drugs & Pharmaceuticals (WELCURE) reported revenue ₹366 Cr, net profit ₹-5 Cr and EPS ₹-0.04, with a net profit margin of -1.4% and ROE of -5.2%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Also explore WELCURE share price history to track price trends across different timeframes.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin -1.37% 2026 data
EBITDA Margin -1.91% 2026 data
Operating Margin -2.00% 2026 data
Return on Assets -0.98% 2026 data
Return on Equity -5.15% 2026 data

Balance Sheet Ratios

Equity Ratio 19.02% 2026 data
Asset Turnover 0.72 2026 data

WELCURE Revenue, Net Profit & EBITDA — Year-on-Year Growth

WELCURE YoY (March 2025 vs March 2026) — revenue +1255.6%, net profit -350.0%, EBITDA -333.3%, expenses +1450.0%. Analyse Welcure Drugs & Pharmaceutical ownership pattern to track promoter, FII and institutional holdings.

Revenue Growth
+1255.6%
Year-over-Year
Net Profit Growth
-350.0%
Year-over-Year
EBITDA Growth
-333.3%
Year-over-Year
Expense Growth
+1450.0%
Year-over-Year
Assets Growth
+91.0%
Year-over-Year
Equity Growth
-5.8%
Year-over-Year

WELCURE Income Statement — Revenue, EBITDA & Net Profit

Welcure Drugs & Pharmaceuticals revenue ₹366 Cr, EBITDA ₹-7 Cr, net profit ₹-5 Cr, EPS ₹-0.04 (2026) — net profit margin -1.4%. For live price, earnings ratios and company overview, see Welcure Drugs & Pharmaceutical stock price NSE.

Periods ₹ Crores
Particulars March 2026 March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Revenue 366 27 0 0 0 0 0 0 0 0 0 0
Expenses 372 24 0 0 0 0 0 0 0 0 0 0
EBITDA -7 3 0 0 0 0 0 0 0 0 0 0
Operating Profit Margin % -2.00% 4.00% 0.00% 0.00% 22.00% 41.00% -12.00% 3.00% -41.00% 31.00% 32.00% 7.00%
Depreciation 0 0 0 0 0 0 0 0 0 0 0 0
Interest 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax -5 3 0 0 0 0 0 0 0 0 0 0
Tax 0 1 0 0 0 0 0 0 0 0 0 0
Net Profit -5 2 0 0 0 0 0 0 0 0 0 0
Earnings Per Share (₹) -0.04 0.36 -0.13 0.08 0.02 0.05 -0.01 0.00 -0.02 0.02 0.07 0.00

WELCURE Balance Sheet — Assets, Liabilities & Shareholders' Equity

WELCURE total assets ₹510 Cr, total equity ₹97 Cr, total liabilities ₹ Cr (2026) — ROE -5.2%.

Years Annual Data ₹ Crores
Particulars 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
ASSETS
Total Assets 510 267 1 2 0 0 0 0 0 0 0 0
Current Assets 358 182 0 0 0 0 0 0 0 0 0 0
Fixed Assets 0 0 0 0 0 0 0 0 0 0 0 0
Capital Work in Progress 0 0 0 0 0 0 0 0 0 0 0 0
Investments 144 0 0 0 0 0 0 0 0 0 0 0
Other Assets 0 267 1 1 0 0 0 0 0 0 0 0
LIABILITIES
Total Liabilities
Current Liabilities 0 123 0 0 0 0 0 0 0 0 0 0
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 97 103 1 2 0 0 0 0 0 0 0 0
Share Capital 124 112 13 13 12 12 12 12 12 12 12 12
Reserves & Surplus -27 -10 -12 -12 -12 -12 -12 -12 -12 -12 -12 -12

WELCURE Cash Flow Statement — Operating, Investing & Financing

Welcure Drugs & Pharmaceuticals operating cash flow ₹-222 Cr, investing ₹0 Cr, financing ₹222 Cr, net cash flow ₹0 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Operating Activities -222 0 0 0 0 0 0 0 0 0 0
Investing Activities 0 0 0 0 0 0 0 0 0 0 0
Financing Activities 222 0 0 0 0 0 0 0 0 0 0
Net Cash Flow 0 0 0 0 0 0 0 0 0 0 0